As regulations and requirements for transparent interactions between pharmaceutical, medical device and biotechnology companies (collectively “life sciences organizations” or “LSOs”), and healthcare professionals (“HCPs”) continue to evolve, certain patterns are emerging. It is becoming increasingly important to protect prescribers and companies by ensuring that transactions are commercially reasonable and FMV compliant.
